Rabbit Recombinant Monoclonal IFITM1 antibody - conjugated to Alkaline Phosphatase.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: 50% Glycerol (glycerin, glycerine), 1% BSA, 0.016% Magnesium chloride, 0.001% Zinc chloride
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) (PubMed:26354436, PubMed:33270927). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry and SARS-CoV and SARS-CoV-2 S protein-mediated viral entry. Also implicated in cell adhesion and control of cell growth and migration (PubMed:33270927). Inhibits SARS-CoV-2 S protein-mediated syncytia formation (PubMed:33051876). Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activation or by arresting cell growth in G1 phase in a p53-dependent manner. Acts as a positive regulator of osteoblast differentiation. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed:26354436). IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed:26354436).
CD225, IFI17, IFITM1, Interferon-induced transmembrane protein 1, Dispanin subfamily A member 2a, Interferon-induced protein 17, Interferon-inducible protein 9-27, Leu-13 antigen, DSPA2a
Rabbit Recombinant Monoclonal IFITM1 antibody - conjugated to Alkaline Phosphatase.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: 50% Glycerol (glycerin, glycerine), 1% BSA, 0.016% Magnesium chloride, 0.001% Zinc chloride
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
IFITM1 also known as Interferon-Induced Transmembrane Protein 1 has a molecular weight of approximately 14 kDa. It is a transmembrane protein that plays an important role in host defense mechanisms. IFITM1 is expressed in various tissues including the respiratory tract gastrointestinal tract and the immune system where it serves in defending against pathogenic infections. The protein is usually found on the cell membrane and becomes highly expressed in response to interferon signaling.
This protein inhibits viral entry by restricting the fusion of viral membranes with host cell membranes. IFITM1 does not function alone; it is part of the IFITM family which includes IFITM2 and IFITM3 each contributing to antiviral defense. The protein is strategically positioned to prevent the spread of viruses by blocking them from entering new cells which is important for managing viral propagation.
IFITM1 engages the innate immune response pathway responding to viral infections by acting as a barrier to viral entry. It works alongside related proteins such as IFITM2 and IFITM3 within this pathway. IFITM1 is also part of the interferon pathway where its expression is upregulated in response to interferon signals. This relationship highlights its role in the immune response acting as a frontline protector against the invasion of viruses like influenza and others.
IFITM1 has a significant role in the context of viral infections and certain cancers. It is linked to resistance to viral infections such as influenza showing its importance in antiviral defense. In cancer aberrant expression of IFITM1 is observed in various types including breast and colorectal cancers impacting tumor progression and metastasis. The relationship of IFITM1 with interferon signaling highlights potential therapeutic targets where modulating its activity could influence disease outcomes.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com